| Jason T Fancey, MD | |
|
302 University Pkwy, Aiken, SC 29801-6302 | |
| (803) 641-5000 | |
| Not Available |
| Full Name | Jason T Fancey |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 28 Years |
| Location | 302 University Pkwy, Aiken, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255386629 | NPI | - | NPPES |
| 223608 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 22360 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| High Point Regional Health System | High point, NC | Hospital |
| North Carolina Baptist Hospital | Winston-salem, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wake Forest University Health Sciences | 4486564952 | 1987 |
News Archive
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received a subpoena from the Office of Inspector General ("OIG") of the Department of Health and Human Services ("HHS") in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.
New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.
Revolutions Medical met with interested global distributors and showed, for the first time, the new market samples of its 3ml RevVac Safety syringe.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.
› Verified 1 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received a subpoena from the Office of Inspector General ("OIG") of the Department of Health and Human Services ("HHS") in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.
New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.
Revolutions Medical met with interested global distributors and showed, for the first time, the new market samples of its 3ml RevVac Safety syringe.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.
› Verified 1 days ago
| Entity Name | North State Pathology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295792430 PECOS PAC ID: 0547394975 Enrollment ID: O20100819001120 |
News Archive
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received a subpoena from the Office of Inspector General ("OIG") of the Department of Health and Human Services ("HHS") in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.
New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.
Revolutions Medical met with interested global distributors and showed, for the first time, the new market samples of its 3ml RevVac Safety syringe.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason T Fancey, MD Po Box 49009, Greenwood, SC 29649-0001 Ph: (864) 223-3070 | Jason T Fancey, MD 302 University Pkwy, Aiken, SC 29801-6302 Ph: (803) 641-5000 |
News Archive
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received a subpoena from the Office of Inspector General ("OIG") of the Department of Health and Human Services ("HHS") in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities.
New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.
Revolutions Medical met with interested global distributors and showed, for the first time, the new market samples of its 3ml RevVac Safety syringe.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.
› Verified 1 days ago
Peter A. Zvejnieks, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 302 University Pkwy, Aiken, SC 29801 Phone: 803-641-5000 | |
Michael M Boyd, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 302 University Pkwy, Pathology Department, Aiken, SC 29801 Phone: 803-641-5170 | |
Robert Layton Williams, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 302 University Pkwy, Aiken Regional Medical Centers Pathology Dept., Aiken, SC 29801 Phone: 803-641-5171 Fax: 803-641-5140 | |
Dr. Trent Damian Trzpuc, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 302 University Pkwy, Aiken Regional Medical Centers Pathology Dept., Aiken, SC 29801 Phone: 803-641-5172 Fax: 803-641-5140 | |
Bonnie S. Szymik, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 302 University Pkwy, Aiken, SC 29801 Phone: 803-641-5000 | |
Denyse N. Parnell, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 302 University Pkwy, Aiken, SC 29801 Phone: 803-641-5000 Fax: 864-223-1396 |